How French culture influences the framing of genetic modifications on the internet: Insights from Google-based corpus analysis.

Since the mid-1990s, genetically modified (GM) crops and foodstuffs have been the subject of much controversy. While research has highlighted a disparity between attitudes toward the consumption of GM products, this study focuses on the circulation of cultural frameworks for GMs online. We use two datasets obtained using Google as a privileged observation site for understanding how debates regarding genetic engineering are framed in global and local contexts.

A New Web-Based Big Data Analytics for Dynamic Public Opinion Mapping in Digital Networks on Contested Biotechnology Fields.

The expression "public opinion" has long been part of common parlance. However, its value as a scientific measure has been the topic of abundant academic debates over the past several decades. Such debates have produced more variety and contestations rather than consensus on the very definition of public opinion, let alone on how to measure it.

[Understanding the distrust towards the assessment of medicines. Beyond conflict of interests].

This article aims at analyzing mechanisms leading to a situation of mistrust about the scientific evaluation of the medicinal product, beyond issues related to links of interests. The assumption is that conflicts of interest are only one component of this mistrust. It doesn't explain all social controversies affecting this sector, in particular the credibility of drug evaluation systems.

The European Medicines Agency: a public health European agency?

The European Medicines Agency (EMA) is a European Agency as it is a decentralized body governed by European public law; it has its own legal personality and is also distinct from the European Union institutions (Council, Parliament, Commission, etc.). The EMA presents itself, and is commonly recognised, as a public health agency.

The legal landscape for advanced therapies: material and institutional implementation of European Union rules in France and the United Kingdom.

In 2007, the European Union adopted a lex specialis, Regulation (EC) No. 1394/2007 on advanced therapy medicinal products (ATMPs), a new legal category of medical product in regenerative medicine. The regulation applies to ATMPs prepared industrially or manufactured by a method involving an industrial process.

The emergence of clinical practice guidelines.

Clinical practice guidelines are now ubiquitous. This article describes the emergence of such guidelines in a way that differs from the two dominant explanations, one focusing on administrative cost-cutting and the other on the need to protect collective professional autonomy. Instead, this article argues that the spread of guidelines represents a new regulation of medical care resulting from a confluence of circumstances that mobilized many different groups.